Prime Medicine PRME Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -216.1%-101pp | -146.8%-9.9pp | -112.3%+2.0pp | -154.8%-55.2pp | -115.2%-36.9pp | |
| Return on assets | -63.7%-0.5pp | -62.8%+16.9pp | -55%+21.7pp | -74%+6.5pp | -63.2%+1.9pp | |
| Return on invested capital | -175.4%-38.7pp | —— | -138.9%+40.5pp | -144.7%+15.8pp | -136.8%-10.5pp | |
| Liquidity | ||||||
| Current ratio | 3.8×-1.0× | 4.8×-0.7× | 6.6×+0.1× | 3.6×-4.7× | 4.8×-4.1× | |
| Quick ratio | 3.8×-1.0× | 4.8×-0.7× | 6.6×+0.1× | 3.6×-4.7× | 4.8×-4.1× | |
| Cash ratio | 2.1×-0.9× | 2×-3.1× | 2.4×-1.1× | 2×-1.4× | 3.1×-1.3× | |
| Leverage | ||||||
| Debt-to-equity | 1.5×+0.4× | 1×+0.7× | 0.7×+0.5× | 2×+1.8× | 1.1×+1.0× | |
| Debt-to-assets | 0.4×0.0× | 0.3×+0.2× | 0.3×+0.2× | 0.4×+0.3× | 0.4×+0.2× | |
| Per Share | ||||||
| Book value per share | $0.43-47.0% | $0.81-37.1% | $1.01-36.3% | $0.47-71.4% | $0.82-65.0% | |
| Valuation | ||||||
| Market capitalization | $574.36M+111% | $626.37M+63.5% | $987.64M+114% | $283.6M-53.7% | $261.01M-64.3% | |
| Enterprise value | $611.08M+113% | $666.08M+193% | $1.02B+176% | $335.84M-42.6% | $276.22M-58.6% | |
| Price / book | 7.5×+4.9× | 5.2×+2.7× | 6.1×+3.7× | 4.7×+1.5× | 2.4×-0.6× | |
| Free cash flow yield | -27.6%— | -26.7%— | —— | —— | —— | |
| Earnings yield | -34.5%+39.8pp | -32.1%+19.0pp | -20%+27.6pp | -70.3%-34.8pp | -77.4%-49.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Prime Medicine's ratios come from?
- Every ratio is computed from Prime Medicine's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
